Tevogen Bio (@tevogenbio) 's Twitter Profile
Tevogen Bio

@tevogenbio

Specialty immunotherapy biotech developing off-the-shelf precision #Tcell therapeutics in #oncology, #neurology, and #virology. $TVGN

ID: 1371813486544687110

linkhttp://www.tevogen.com calendar_today16-03-2021 13:20:29

417 Tweet

587 Followers

220 Following

Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ ๐‚๐จ๐ง๐ญ๐ซ๐ข๐›๐ฎ๐ญ๐ข๐จ๐ง ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐ฅ๐ž๐š๐๐ž๐ซ๐ฌ๐ก๐ข๐ฉโ€™๐ฌ ๐ฎ๐ง๐๐ž๐ซ๐ฌ๐ญ๐š๐ง๐๐ข๐ง๐  ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ข๐ฆ๐ฉ๐จ๐ซ๐ญ๐š๐ง๐œ๐ž ๐€๐ˆ ๐ฐ๐ข๐ฅ๐ฅ ๐ฉ๐ฅ๐š๐ฒ ๐ข๐ง ๐๐ซ๐ฎ๐  ๐๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ โ€œThis personal investment by our CEO

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ

๐‚๐จ๐ง๐ญ๐ซ๐ข๐›๐ฎ๐ญ๐ข๐จ๐ง ๐ก๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐ฅ๐ž๐š๐๐ž๐ซ๐ฌ๐ก๐ข๐ฉโ€™๐ฌ ๐ฎ๐ง๐๐ž๐ซ๐ฌ๐ญ๐š๐ง๐๐ข๐ง๐  ๐จ๐Ÿ ๐ญ๐ก๐ž ๐ข๐ฆ๐ฉ๐จ๐ซ๐ญ๐š๐ง๐œ๐ž ๐€๐ˆ ๐ฐ๐ข๐ฅ๐ฅ ๐ฉ๐ฅ๐š๐ฒ ๐ข๐ง ๐๐ซ๐ฎ๐  ๐๐ข๐ฌ๐œ๐จ๐ฏ๐ž๐ซ๐ฒ

โ€œThis personal investment by our CEO
Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq) (@ceo_tevogen_bio) 's Twitter Profile Photo

Tevogen: 300+ years of experience in drug development, commercialization, investment banking, & the emerging field of $AI in healthcare. ๐ŸŒtevogen.com/about/#Leadersโ€ฆ #TechInHealthcare #BiopharmaFuture #AIinHealthcare #GrowthCatalyst $TVGN #Leadership #PurposeDriven

Tevogen: 300+ years of experience in drug development, commercialization, investment banking, & the emerging field of $AI in healthcare. 

๐ŸŒtevogen.com/about/#Leadersโ€ฆ

#TechInHealthcare #BiopharmaFuture #AIinHealthcare #GrowthCatalyst $TVGN #Leadership #PurposeDriven
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

โณ ๐“๐ž๐ฏ๐จ๐ ๐ž๐ง ๐“๐ข๐ฆ๐ž ๐‚๐š๐ฉ๐ฌ๐ฎ๐ฅ๐ž โณ Tevogen Bio's positive proof-of-concept clinical trial. Learn more about the results at: ashpublications.org/bloodadvances/โ€ฆ $TVGN #affordable #accessible #celltherapy #clinicaltrials Blood Advances

โณ ๐“๐ž๐ฏ๐จ๐ ๐ž๐ง ๐“๐ข๐ฆ๐ž ๐‚๐š๐ฉ๐ฌ๐ฎ๐ฅ๐ž โณ 

Tevogen Bio's positive proof-of-concept clinical trial. Learn more about the results at: ashpublications.org/bloodadvances/โ€ฆ

$TVGN #affordable #accessible #celltherapy #clinicaltrials <a href="/BloodAdvances/">Blood Advances</a>
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐“๐ฐ๐จ ๐ž๐ง๐ž๐ซ๐ ๐ข๐ณ๐ข๐ง๐  ๐๐š๐ฒ๐ฌ ๐š๐ญ ๐ญ๐ก๐ž CMSGov 2025 ๐๐ฎ๐š๐ฅ๐ข๐ญ๐ฒ ๐‚๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž #๐‚๐Œ๐’๐๐ฎ๐š๐ฅ๐‚๐จ๐ง2025. Reflecting on the event, Tevogenโ€™s Head of Government Affairs and Patient Access, David Banko, commented โ€œDrOzCMS โ€œMake America Healthy Againโ€ fireside

๐“๐ฐ๐จ ๐ž๐ง๐ž๐ซ๐ ๐ข๐ณ๐ข๐ง๐  ๐๐š๐ฒ๐ฌ ๐š๐ญ ๐ญ๐ก๐ž <a href="/CMSGov/">CMSGov</a> 2025 ๐๐ฎ๐š๐ฅ๐ข๐ญ๐ฒ ๐‚๐จ๐ง๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž #๐‚๐Œ๐’๐๐ฎ๐š๐ฅ๐‚๐จ๐ง2025.

Reflecting on the event, Tevogenโ€™s Head of Government Affairs and Patient Access, David Banko, commented โ€œ<a href="/DrOzCMS/">DrOzCMS</a> โ€œMake America Healthy Againโ€ fireside
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

โณ ๐“๐ž๐ฏ๐จ๐ ๐ž๐ง ๐“๐ข๐ฆ๐ž ๐‚๐š๐ฉ๐ฌ๐ฎ๐ฅ๐ž โณ Mittul Mehta CIO and Head of Tevogen.AI in conversation with Brad Mehl of Future Sights and Medium about AI Innovation in Drug Discovery. ๐Ÿ‘‰medium.com/future-sights/โ€ฆ "One of the most interesting use cases that we deal

โณ ๐“๐ž๐ฏ๐จ๐ ๐ž๐ง ๐“๐ข๐ฆ๐ž ๐‚๐š๐ฉ๐ฌ๐ฎ๐ฅ๐ž โณ

Mittul Mehta CIO and Head of Tevogen.AI in conversation with <a href="/bradmehl/">Brad Mehl</a> of <a href="/futuresights_hq/">Future Sights</a> and <a href="/Medium/">Medium</a> about AI Innovation in Drug Discovery.
๐Ÿ‘‰medium.com/future-sights/โ€ฆ 

"One of the most interesting use cases that we deal
Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq) (@ceo_tevogen_bio) 's Twitter Profile Photo

Those nights still returnโ€”the memory of sitting silently beside hospital beds, holding the hands of young parents who were terrified of leaving their children behind. I had nothing to offer but empathy. Every loss felt like a personal failure, and the intense feeling of

Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: tevogen.com/press_release/โ€ฆ Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogenโ€™s previous footprint and brings research, regulatory, and the expanding Tevogen.AI teams together

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: tevogen.com/press_release/โ€ฆ

Completed ahead of schedule, the new facility is designed to anticipate growth as it more than doubles Tevogenโ€™s previous footprint and brings research, regulatory, and the expanding Tevogen.AI teams together
NJBIZ (@njbiz) 's Twitter Profile Photo

Dr. Ryan Saadi, Tevogen Bio founder and CEO, gifts $500,000 for the build-out and first-year operating costs of the company's expanded corporate HQ in Warren. njbiz.com/tevogen-warrenโ€ฆ

Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ $TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence Microsoft Databricks ยท Tevogen.AIโ€™s model drastically reduces target analysis and has the potential to generate billions in cost savings

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ

$TVGN #affordable #accessible #celltherapy #AI #ArtificialIntelligence <a href="/Microsoft/">Microsoft</a> <a href="/databricks/">Databricks</a> 

ยท Tevogen.AIโ€™s model drastically reduces target analysis and has the potential to generate billions in cost savings
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

#๐ˆ๐‚๐˜๐Œ๐ˆ ๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ โ€œThrough the development and utilization of the PredicTcell platform we have uncovered new insights and are able to quickly analyze significantly larger datasets, potentiallyย resulting in better accuracy and

#๐ˆ๐‚๐˜๐Œ๐ˆ
๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ 

โ€œThrough the development and utilization of the PredicTcell platform we have uncovered new insights and are able to quickly analyze significantly larger datasets, potentiallyย resulting in better accuracy and
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ โ–ช Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies โ–ช Initiative to support Tevogen Bioโ€™s ExacTcellโ„ข pipeline with a goal of enhancing commercial viability and

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ

โ–ช Advanced algorithms aim to reduce trial planning timelines, accelerating time-to-market for new therapies
โ–ช Initiative to support Tevogen Bioโ€™s ExacTcellโ„ข pipeline with a goal of enhancing commercial viability and
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ โ€œOur continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,โ€ said Dr. Ryan Saadi, Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq). โ€œThis facility has potential to efficiently scale our

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ

โ€œOur continued investment in infrastructure reflects our commitment to delivering innovative and accessible T cell therapies,โ€ said Dr. Ryan Saadi, <a href="/CEO_TEVOGEN_BIO/">Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq)</a>. โ€œThis facility has potential to efficiently scale our
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity.

๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ

Traditional methods for identifying immunologically active peptides often face significant limitations, such as overlooking critical human genetic diversity factors like age, sex, race, and ethnicity.
Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq) (@ceo_tevogen_bio) 's Twitter Profile Photo

Clinical trial, portfolio, pioneering AI drug-development platforms, infrastructure, & IP โ€” all in just five years โ€” approximately $40M in invested capital โ€” & remains one of the rare, majority insider-owned healthcare companies on a clear growth trajectory. When ROI meets

Clinical trial, portfolio, pioneering AI drug-development platforms, infrastructure, &amp; IP โ€” all in just five years โ€” approximately $40M in invested capital โ€” &amp; remains one of the rare, majority insider-owned healthcare companies on a clear growth trajectory. When ROI meets
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

#๐ˆ๐‚๐˜๐Œ๐ˆ ๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ โ€œIโ€™m pleased with Tevogen.AIโ€™s continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,โ€ said Dr. Ryan Saadi, Founder and Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq).

#๐ˆ๐‚๐˜๐Œ๐ˆ
๐Ÿ“ฐ ๐๐ซ๐ž๐ฌ๐ฌ ๐‘๐ž๐ฅ๐ž๐š๐ฌ๐ž: globenewswire.com/news-release/2โ€ฆ 

โ€œIโ€™m pleased with Tevogen.AIโ€™s continued progress in strategically harnessing artificial intelligence in support of our cell therapy development,โ€ said Dr. Ryan Saadi, Founder and <a href="/CEO_TEVOGEN_BIO/">Ryan Saadi, CEO, Tevogen Bio ($TVGN @nasdaq)</a>.
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

โณ ๐“๐ž๐ฏ๐จ๐ ๐ž๐ง ๐“๐ข๐ฆ๐ž ๐‚๐š๐ฉ๐ฌ๐ฎ๐ฅ๐ž โณ Team Tevogen at the 2022 New York Bio "Emerging Life Science Company Showcase" hosted by NYSE ๐Ÿ› $TVGN #affordable #accesible #celltherapy #biotech

โณ ๐“๐ž๐ฏ๐จ๐ ๐ž๐ง ๐“๐ข๐ฆ๐ž ๐‚๐š๐ฉ๐ฌ๐ฎ๐ฅ๐ž โณ

Team Tevogen at the 2022 New York Bio "Emerging Life Science Company Showcase" hosted by <a href="/NYSE/">NYSE ๐Ÿ›</a> 

$TVGN #affordable #accesible #celltherapy #biotech
Tevogen Bio (@tevogenbio) 's Twitter Profile Photo

Advanced Research Projects Agency for Health ARPA-H FRONT (Functional Repair of Neocortical Tissue) program is specifically targeting over 20 million U.S. adults living with chronic neocortical brain damage due to stroke, neurodegeneration (like Alzheimerโ€™s), and traumatic brain